# Synchrony Financial (SYF)

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-29  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/SYF/primer

## Business Model

---
source: coverage-next-full | ticker: SYF | step: "01" | created: 2026-05-29
---

### Step 01 — Business Overview: Synchrony Financial (SYF)

#### One-Line Description
Synchrony Financial is the largest issuer of private-label credit cards (PLCCs) in the United States, operating a co-branded consumer lending business across 5 vertical platforms serving ~70 million active accounts and $182B in annual purchase volume.

#### Corporate Profile
- **CEO:** Brian Doubles (since April 2021; joined SYF 2013, served as CFO 2014–2021)
- **CFO:** Brian Wenzel (EVP & CFO; 20+ year SYF/GE Capital veteran)
- **Headquarters:** Stamford, CT
- **Employees:** ~20,000
- **Banking Charter:** Synchrony Bank (Utah state-chartered, FDIC-insured, OCC-regulated)
- **Market Cap (May 2026):** ~$24.0B
- **S&P 500 member:** Yes (added 2015)

#### Core Business Model
Synchrony partners with merchants, retailers, healthcare providers, and digital platforms to issue co-branded or private-label credit cards under the partner's brand. The economics work as follows:
1. **Partner acquires customer** via point-of-sale application (in-store or digital)
2. **SYF underwrites, funds, and services** the credit account
3. **Customer revolves a balance** — SYF earns net interest income (~15% NIM) on receivables
4. **Partner receives RSA (retailer share arrangement)** — SYF pays back a portion of net income generated on their customer portfolio. RSAs align incentives and retain partners but are SYF's primary variable cost.
5. **SYF retains the credit risk** — this is the fundamental trade: SYF takes the charge-off risk in exchange for the high-yield spread

#### Five Sales Platforms
| Platform | Focus | Key Partners | Approx. Portfolio Share |
|---|---|---|---|
| Home & Auto | Home improvement, auto parts/services, outdoor power | Lowe's, Ashley Furniture, TJX, Kawasaki, Polaris, Husqvarna | ~30% |
| Digital | Online-native, general-purpose/PLCC | PayPal, eBay, Amazon (legacy, winding down) | ~20% |
| Diversified & Value | Retail, specialty merchants, value-oriented | Sam's Club (Walmart), Dick's Sporting Goods, Guitar Center, American Eagle | ~20% |
| Health & Wellness | Healthcare financing (CareCredit brand) | 270,000+ provider locations — dental, veterinary, vision, cosmetic, specialty medical | ~18% |
| Lifestyle | Specialty consumer: jewelry, music, power sports | Pandora, Sweetwater, Guitar Center (co-brand) | ~12% |

**CareCredit** is the crown jewel of the Health & Wellness platform — the leading point-of-care healthcare financing brand with no direct competitor at scale. It enables patients to finance medical/dental procedures at the point of care (dentist, vet, optometrist offices), creating a B2B2C network effect.

#### Key Partners (Selected)
| Partner | Platform | Estimated Receivables Contribution |
|---|---|---|
| Lowe's | Home & Auto | ~10–12% of total receivables |
| Sam's Club (Walmart) | Diversified & Value | ~8–10% |
| PayPal | Digital | ~8–10% |
| Amazon | Digital | Wind-down; declining |
| CareCredit network | Health & Wellness | ~18% of receivables |
| Ashley Furniture | Home & Auto | ~3–4% |
| Dick's Sporting Goods | Diversified & Value | ~3–4% |
| Guitar Center | Lifestyle/D&V | ~2–3% |
| American Eagle | Diversified & Value | ~2–3% |

#### Scale Metrics (FY2025 / Latest)
- **Active Accounts:** ~70.7M (period-end 2025)
- **Purchase Volume:** $182.3B (FY2025)
- **Loan Receivables:** $103.8B gross / $93.4B net (FY2025)
- **Partners:** 500+ across all platforms
- **Provider Locations (CareCredit):** 270,000+
- **Digital Applications:** 57% of consumer revolving credit applications via digital channels

#### What SYF Is NOT
- **Not a general-purpose issuer:** Unlike Capital One or Citi, SYF does not primarily issue cards consumers independently seek. Its cards are anchored to a specific retail or healthcare relationship.
- **Not a payment network:** SYF does not own a payment network (Visa/MC branding is used for co-brands; Discover network in some cases). Card issuance ≠ network economics.
- **Not a transaction processor:** SYF books receivables, not merchant services revenue.

#### Competitive Position
- **#1 US PLCC issuer** by receivables and active accounts
- **PLCC market share:** ~35–40% (vs. Bread Financial/Comenity ~20%, Citi Retail Services ~15%)
- **CareCredit:** Dominant position in healthcare point-of-care financing with no direct at-scale competitor
- **Revenue per account:** Higher than bank card averages due to revolving credit emphasis; PLCC users revolve more than GP card users

#### Key Investment Considerations (Preview)
1. **Credit normalization:** NCO rates elevated 2022–2024 following COVID-era charge-off suppression; 2025 saw improvement (5.65% NCO in FY2025 vs. 6.31% in FY2024). Full normalization is the key earnings lever.
2. **Buyback-driven EPS growth:** Share count reduced ~36% since 2014 IPO. $6.5B buyback authorized Q1 2026 at <5x earnings.
3. **CFPB regulatory overhang lifted:** The proposed CFPB $8 late fee cap was vacated by courts in 2025, removing the primary tail risk.
4. **Partner portfolio renewal:** Lowe's contract renewal and post-Amazon transition set the pace for the Digital platform rebuild.

## Financial Snapshot

---
source: coverage-next-full | ticker: SYF | step: "04" | created: 2026-05-29
---

### Step 04 — Financial Snapshot: Synchrony Financial (SYF)

#### Five-Year P&L Summary (USD Millions)

| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Net Interest Income | $9,711 | $11,294 | $13,338 | $14,604 | $14,461 |
| Non-Interest Income | $481 | $380 | $289 | $1,521 | $520 |
| **Total Net Revenue** | **$9,466** | **$8,299** | **$7,662** | **$9,392** | **$9,756** |
| Provision for Credit Losses | $726 | $3,375 | $5,965 | $6,733 | $5,225 |
| Operating Expenses | ~$2,000 | ~$2,500 | ~$2,430 | ~$2,820 | ~$3,400 |
| Pre-Tax Income | ~$5,600 | ~$3,900 | ~$2,900 | ~$4,200 | ~$4,500 |
| Net Income | **$4,179** | **$2,974** | **$2,196** | **$3,427** | **$3,469** |
| Diluted EPS | $7.34 | $6.15 | $5.19 | $8.55 | $9.28 |
| Shares Outstanding (period-end, M) | 527 | 438 | 407 | 389 | 347 |
| Diluted Shares (avg, M) | ~569 | ~484 | ~423 | ~401 | ~374 |

**Revenue note:** "Total Net Revenue" as reported by SYF = Net Interest Income + Other Income (Non-Interest), but then Provision for Credit Losses is subtracted to arrive at Net Revenue After Provision. StockAnalysis reports "Revenue" on a net-of-provision basis. The table above follows SYF's IR reporting convention (NII + non-interest before provision).

**FY2021 note:** Elevated net income reflects COVID-era reserve release; provision was ultra-low ($726M vs. normalized ~$4–6B) as stimulus payments suppressed charge-offs and SYF released ACL reserves built in FY2020.

#### Per-Share Metrics

| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| EPS (Diluted) | $7.34 | $6.15 | $5.19 | $8.55 | $9.28 |
| Dividends Per Share | $0.88 | $0.92 | $0.92 | $0.96 | $1.00 |
| Book Value Per Share | $23.99 | $26.63 | $32.83 | $41.39 | $46.88 |
| Tangible Book Value/Share | ~$23.50 | ~$26.10 | ~$32.20 | ~$40.70 | ~$46.20 |
| P/E (year-end) | ~11x | ~5x | ~10x | ~6x | ~7x |
| P/TBV (year-end) | ~2.0x | ~0.8x | ~0.9x | ~0.7x | ~1.0x |

*Tangible book ≈ book value less ~$0.7B goodwill/intangibles (primarily from Ally Lending acquisition in 2023 and Pets Best).*

#### Key Profitability Metrics

| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Net Interest Margin (NIM) | ~12.8% | ~13.5% | ~14.2% | 14.76% | 15.24% |
| Net Charge-Off (NCO) Rate | ~2.0% | ~3.6% | ~5.9% | 6.31% | 5.65% |
| 30+ Day Delinquency Rate | ~2.4% | ~3.5% | ~4.8% | 4.70% | 4.49% |
| Return on Assets (ROA) | ~4.4% | ~2.8% | ~2.1% | 2.9% | 3.0% |
| Return on Equity (ROE) | ~31% | ~22% | ~16% | ~21% | ~21% |
| Efficiency Ratio | ~21% | ~30% | ~33% | 30.0% | 34.3% |
| CET1 Capital Ratio | ~11.5% | ~11.3% | ~12.0% | 13.3% | 12.6% |

**NIM trend:** NIM expanded from ~12.8% (FY2021) to 15.24% (FY2025) — reflecting higher-for-longer rate environment pushing PLCC APRs (which are prime-indexed) higher, partially offset by rising deposit costs.

**NCO cycle:** FY2021 was the trough (COVID stimulus suppressed defaults). FY2022–2024 saw normalization and overshoot as consumers exhausted savings. FY2025 shows improvement; full normalization target ~4.5%.

#### Balance Sheet Summary

| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total Assets | $95,748 | $104,564 | $117,479 | $119,463 | $119,095 |
| Gross Loan Receivables | $80,740 | $92,470 | $102,988 | $104,721 | $103,808 |
| Net Loan Receivables | $72,052 | $82,943 | $92,417 | $93,792 | $93,366 |
| Total Deposits | $62,270 | $71,735 | $81,153 | $82,062 | $81,144 |
| Long-Term Debt | $14,507 | $14,191 | $15,982 | $15,462 | $15,182 |
| Shareholders' Equity | $13,655 | $12,873 | $13,903 | $16,580 | $16,766 |

**Asset growth:** SYF's receivables grew from $80.7B (FY2021) to $103.8B (FY2025), a ~29% increase over 4 years, despite deliberate portfolio tightening in 2023–2024. Growth came from organic expansion and the Ally Lending acquisition (~$2.2B, March 2023).

#### Cash Flow Summary

| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $7,099 | $6,694 | $8,593 | $9,848 | $9,851 |
| Capital Expenditures | ~$0 | ~$0 | ~$0 | ~$0 | ~$0 |
| Free Cash Flow | $7,099 | $6,694 | $8,593 | $9,848 | $9,851 |
| Dividends Paid | $500 | $434 | $406 | $398 | $427 |
| Share Repurchases | $2,876 | $3,320 | $1,112 | $1,008 | $2,941 |
| Total Capital Returned | $3,418 | $3,796 | $1,560 | $1,478 | $3,451 |

*FCF definition for financial companies: Operating cash flow because capex is minimal and economic capex is embedded in operating expenses (technology, personnel).*

#### Consensus Estimates (FY2026–FY2027)

| Metric | FY2025A | FY2026E | FY2027E |
|---|---|---|---|
| Revenue (net basis) | $9,756M | ~$10,200–10,600M | ~$11,000–11,500M |
| EPS (Diluted) | $9.28 | ~$8.50–9.50 | ~$9.50–11.00 |
| Net Income | $3,469M | ~$3,100–3,400M | ~$3,400–3,800M |

*Note: FY2026E consensus shows some EPS moderation vs FY2025 due to lower non-interest income (Pets Best divestiture gain was one-time in FY2024; FY2025 already excluded it). The EPS run-rate excluding one-time items is ~$9–10 and trending up as credit normalizes.*

#### Valuation Summary (May 2026)
- **Share price (approx.):** ~$65–70
- **Market Cap:** ~$22–24B
- **P/Diluted EPS (TTM):** ~7x
- **P/Tangible Book Value:** ~1.4–1.5x
- **Dividend yield:** ~1.5%
- **Dividend payout ratio:** ~11% (very low; most capital returned via buybacks)

#### Key Takeaways
1. **EPS growth is structurally driven by buybacks** — diluted shares fell from 569M (FY2021 avg) to ~374M (FY2025 avg), a 34% reduction. Even flat net income produces meaningfully growing EPS.
2. **NIM expansion is genuine** — 15.24% NIM is near the high end of historical range, supported by prime-indexed PLCC APRs. Rate cuts should not materially compress NIM in near term.
3. **NCO normalization is the key forward catalyst** — returning to 4.5% from 5.65% would reduce provision ~$1.2B, adding ~$0.85B after-tax to earnings.
4. **Book value per share has nearly doubled since 2021** — from $24 to $47, reflecting retained earnings accumulation even while returning capital via buybacks.

## Recent Catalysts

---
source: coverage-next-full | ticker: SYF | step: "12" | created: 2026-05-29
---

### Step 12 — Catalysts & Scenario Framework: Synchrony Financial (SYF)

#### Near-Term Catalysts (6–18 Months)

##### 1. Credit Normalization Inflection Point
- **What:** NCO rate declining from 5.65% (FY2025) toward 4.5–5.0% range
- **Timeline:** Each quarterly earnings report (Q2 2026 onward)
- **Mechanism:** Each 50bps NCO improvement reduces annual provision by ~$500M → $0.35–0.40/share after-tax EPS lift
- **Catalyst event:** Q2 or Q3 2026 earnings showing NCO rate <5.0% would be a decisive sentiment inflection

##### 2. $6.5B Buyback Execution
- **What:** $6.5B authorized (April 2026) being executed at ~$65–70/share
- **Timeline:** Over 12–18 months (estimated completion by Q3 2027)
- **Mechanism:** Every $1B repurchased at $67 retires ~15M shares; at current EPS reduces share count ~4.5% per billion
- **Catalyst event:** Quarterly reports showing accelerating share count reduction

##### 3. EPS Inflection From Combined Effects
- **What:** NCO improvement + share count reduction compounding
- **Timeline:** Q2 2026–FY2027
- **Bull scenario math:** FY2027E EPS at 4.5% NCO + 300M shares = ~$12–14/share
- **Catalyst event:** Consensus upgrades when analysts recognize normalization path

##### 4. CareCredit Expansion
- **What:** New provider category expansion (med-surg, behavioral health, veterinary specialty)
- **Timeline:** Ongoing; 2–3 notable expansion announcements/year
- **Mechanism:** Each 10,000 new provider locations adds ~$400–600M in receivables over 2–3 years

##### 5. New Partnership Announcements
- **What:** Major new PLCC/co-brand partner sign
- **Timeline:** Unpredictable; typically 1–3 meaningful announcements per year
- **Mechanism:** A $3–5B receivables opportunity with a major retailer adds ~$0.50–1.00/share to normalized EPS

#### Valuation Catalysts

##### Multiple Re-Rating
- **Current:** ~7x earnings, ~1.4x TBV — near historical trough
- **Normal:** 10–12x earnings, 2.0x TBV (when credit cycle is benign)
- **Catalyst:** When investors become convinced NCO normalization is durable (1–2 quarters of clear improvement)
- **Price target (normalized):** $95–115 at 10–12x $9.50–$9.75 normalized EPS (FY2026E street range); $120–140 at fully normalized EPS

---

**Bull Case**
- NCO rates normalize to 4.5% by FY2027, driven by 2022–2023 vintage quality improvement and continued underwriting discipline; combined with the $6.5B buyback reducing share count to ~240M, EPS inflects to $14–16 by FY2027; multiple re-rates from 7x to 10x as investors recognize credit cycle has turned, yielding a price target of $140–160
- CareCredit expands into medical/surgical and behavioral health categories, adding 50,000+ new provider locations over 2025–2027 and growing H&W platform receivables from ~$19B to $25B+, creating a defensible non-cyclical earnings buffer that justifies premium multiple over PLCC peers
- Capital One/Discover post-merger integration delays provide SYF a 2–3 year window to sign major new PLCC partnerships (potential candidates: Home Depot, Target specialty cards, new healthcare networks) that were previously competed away, accelerating receivables growth to 5–7% annually by 2027

**Bear Case**
- US recession in 2026 drives unemployment from ~4.2% to 6.5%+, re-escalating NCO rates to 7–8%, requiring elevated provisioning that wipes out the expected credit normalization benefit; EPS stays in the $5–7 range through 2027 and the $6.5B buyback is paused to preserve capital adequacy above CET1 minimum
- Walmart renegotiates the Sam's Club co-brand contract at materially worse RSA economics for SYF (repeating the history of Walmart's relationship with Capital One), removing ~$9B in high-quality receivables and ~$0.80–1.20/share in EPS; the stock re-rates to 6–7x depressed earnings on partner concentration fears
- A Democratic administration in 2028 reinstates an aggressive CFPB, re-proposing late fee caps and potentially capping interest rates on PLCCs; the regulatory overhang that drove SYF's 2023 derating returns, creating a valuation ceiling of 7–8x earnings and preventing the multiple expansion required for the bull thesis to play out

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/syf
- Full research API: GET /api/v1/research/SYF/memo
- Coverage universe: /stocks